Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
ABBOTT LABORATORIES
Bear Case (25th pct.)
-45.1% vs price
Base Case (Median)
-34.5% vs price
Bull Case (75th pct.)
-24.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $85.93 | -15.7% | High (40%) |
| PE Comparable | $68.28 | -33.0% | Medium (25%) |
| Growth Trajectory DCF | $66.75 | -34.5% | Medium (20%) |
| Graham Number | $45.63 | -55.2% | Medium (40%) |
| EV/EBITDA | $63.15 | -38.1% | Medium (20%) |
| EV/FCF | $86.68 | -15.0% | Medium (20%) |
| Earnings Power Value | $48.82 | -52.1% | Medium (50%) |
Based on 7 out of 7 methods, ABT appears overvalued at the current price of $101.95. The base case fair value of $66.75 implies 34.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.